Gene therapy for age-related muscle loss and heart health
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This trial tests a gene therapy that may help rebuild muscle and improve blood vessel growth in people ages 35 to 75. It's designed for those with stable health conditions and no history of cancer, heart disease, blood clots, or diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 35 and 75 years old
- You have stable health conditions that have not changed in the last 3 months
- You are willing to undergo gene therapy and follow the study schedule
- You have not had cancer or a strong family history of cancer
- You do not have serious heart disease, blood clots, or diabetes
- You are not currently taking medications that affect bleeding or the immune system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy for people with heart failure who still have normal pumping strength (preserved ejection fraction). It aims to improve how heart cells handle calcium, which may help the heart relax better and ease symptoms.
This trial tests a gene therapy injected into the heart to help it recover after a previous heart attack. It may be an option for people with stable heart failure who are not eligible for standard procedures like stents or bypass surgery.
This trial tests a one-time gene therapy that delivers a corrected copy of the frataxin gene directly to the heart. It aims to improve or stabilize heart function in people with Friedreich's ataxia who have early or advanced heart involvement.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
This trial tests a gene therapy for people with alpha-1 antitrypsin deficiency who have mild to moderate lung disease. The aim is to see if the treatment can improve lung health and is safe.
This trial tests a gene therapy for people with a specific mutation (S295L) in the SLC6A1 gene, which causes a neurodevelopmental disorder. The therapy aims to correct the genetic issue, and participants will be monitored closely for safety and effectiveness.
Hear when a new Age-related Muscle Decline trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.